Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
for full faculty bio's, please visit our FACULTY page
Learn about John Cherol, EGFR patient

*** update - John sadly passed away in January of 2018 at the very young age of 30. Our hearts are heavy with sadness. Condolences to his loving family. https://www.waskofamily.com/notices/John-Cherol***
John Cherol was diagnosed in January 2016 with Stage IV EGFR+ lung cancer at the age of 28. He started Gilotrif (afatinib) and acquired resistance after 14 months. Luckily a blood test showed he developed the t790m mutation and he started Tagrisso in April of this year. He’s also been treated for nine brain mets with Gamma Knife at the Cleveland Clinic.
John is a graduate of Youngstown State University with a bachelor’s degree in computer forensics. He currently works as a Senior Cyber Security Analyst in Pittsburgh, PA. He got engaged shortly after his diagnosis to his fiancé, Kristine, who he met in 2014. They’re actively planning their September 9th wedding and a honeymoon to Iceland. Thanks to targeted therapy, John has been able to continue some of the hobbies he loves most like camping and kayaking. He hopes to help change the face of lung cancer and enjoy many more evening walks with Kristine and their rescue dog Liam.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.